VR-Based Optokinetic Stimulation in Multiple Sclerosis
Launched by AVRASYA UNIVERSITY ·
Trial Information
Current as of October 17, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special type of virtual reality (VR) therapy, called optokinetic stimulation, affects balance and feelings of motion sickness in people with multiple sclerosis (MS). The goal is to see if this VR treatment can help reduce problems with standing steady and feeling dizzy or sick from movement.
The study is looking for adults with MS to participate, and it’s open to all genders. While the age range listed seems unusual, it’s best to check with the study team for specific eligibility. If you join, you would experience sessions using VR technology designed to gently stimulate your eyes and brain to improve balance. The trial is not yet recruiting, so it’s a good idea to stay in touch for updates if you or a loved one might be interested.
Gender
ALL
Eligibility criteria
About Avrasya University
Avrasya University is a distinguished academic institution dedicated to advancing medical research and clinical trials. With a commitment to fostering innovation in healthcare, the university integrates cutting-edge research methodologies with a multidisciplinary approach. Its clinical trial sponsorship emphasizes rigorous scientific protocols, ethical standards, and collaboration with healthcare professionals, aiming to contribute significantly to the understanding and treatment of various medical conditions. Avrasya University is dedicated to enhancing patient outcomes and promoting evidence-based practices through its comprehensive research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported